Top of page Skip navigation

    Register today...


    Join us for some great networking

8.00 - 09.15

Registration, networking, breakfast and partnering

9.15 - 09.30

Welcome and BIA Update 

Steve Bates  OBE
Chief Executive Officer, BIA

9.30 - 09.50

Opening Keynote Presentation

Professor Sir John Bell
Regius Professor of Medicine, Oxford University

9.50 - 10.30

Alzheimer’s Research UK - Bridging the gap between academia and industry 

In this session, we’ll hear from experts on how charities can help progress research from academia towards drug discovery.  Dr David Reynolds, CSO, ARUK will lead this interactive panel discussion and explain how ARUK is helping to do this , the Interconnectivity with industry, addressing key gaps and progressing research towards patient benefit and citizen science and technology approaches to improving public understanding.  We’ll also address the need for further investment.

Dr David Reynolds
Chief Scientific Officer, Alzheimer's Research UK

Dr Peter Atkinson 
Associate Director, Head of UK Open Innovation - Neurology Business Group, Eisai

Dr Laurence Barker
Chief Business Officer - Dementia Discovery Fund, SV Health Investors   

John Davis 
Chief Scientific Officer, ARUK Drug Discovery Alliance

Andy Morris
Patient Advocate

10.30 - 11.00

BBSRC Innovator of the Year

Blue sky research helps protect our eyes from phototoxic blue skies

An open mind and ability to connect disparate ideas, combined with academic freedom provided by BBSRC funding and a supportive PI, enabled Dr Temple to translate methods developed during his core research into a new medical device that provides an affordable, easy and rapid method of measuring an aspect of human eye health: the density of macular pigments in the retina. Macular pigments are obtained only from your diet but get depleted by phototoxic blue light. Low levels of these carotenoids result in poor contrast sensitivity and a reduced ability to deal with glare, and have been linked to an increased likelihood of blindness due to Age-related Macular Degeneration, the leading cause of incurable blindness in the western world.

In this presentation will hear about the research that led to his invention as well as provide some background about why we should be measuring macular pigments and how our device will make this available to everyone.  He will share some of his experiences along a path from academia to commercial enterprise and talk about ways to encourage translational bioscience.

Dr Shelby Temple
Co-Founder, Inventor/ and Chief Technical Officer, Azul Optics 

11.00 - 11.30

 Refreshments, networking, exhibition and partnering

11.30 - 13.00

Parallel Tracks

11.30 - 12.15

Top considerations for protecting your innovations through IP

The legal landscape for protecting your IP is constantly changing. This session will equip you with the latest information you need to consider when designing your IP strategy.

We will be joined by Michael Tappin QC – who is widely acclaimed as one of the leading barristers for biotech and pharmaceuticals patent cases – to explain the implications of the recent UK Supreme Court ruling in Lilly vs Actavis, which introduced a new two-step process to determine if a patent infringes another due to equivalence.

A panel of experienced members of the BIA’s IP Advisory Committee will then discuss other recent developments in IP case law and upcoming policy developments that will impact BIA members’ ability to protect their innovations.

Nicola Baker-Munton
Chief Executive Officer, Stratagem IPM

Keynote speaker
Michael Tappin QC

Andrew Hutchinson
Partner, Simmons & Simmons 

Nicole Jadjea
Partner, Fieldfisher 

Susie Middlemiss
Partner, Slaughter and May 

Gareth Morgan
Partner, CMS Cameron McKenna Nabarro Olswang 


Accelerating next generation medicines manufacturing

This session will discuss the advances in manufacturing of traditional biologics, next generation antibodies and cell and gene therapies, including the move from traditional centralised production models to smaller batches to deliver the precision medicines of the future.

Dr Kit Erlebach
Head of R&D Continuous Improvement, FUJIFILM Diosynth Biotechnologies 

Dr Steve Flatman
Head of Research and Development Clinical Development Manufacturing, Lonza

Dr Jim Mills
Vice President Technical Operations, Abzena 

Dr Angela Osborne
Managing Director, eXmoor Pharma Concepts 



Cooperating to solve the key diagnostic challenges faced by the NHS

Public Health England have joined hands with NIHR to convene this session which will look at some of the key diagnostic challenges faced by the NHS in a domestic as well as global health context. 

The UK is making great strides in diagnostic innovations – for example PHE has worked with universities, SMEs and big companies and filed patents in TB, Sepsis, etc. If these innovations are not evaluated and commercialised promptly, they will not benefit patients and the NHS will be left with major diagnostic challenges in key clinical areas.

Generating information on the clinical and cost-effectiveness of in vitro diagnostic devices is therefore very important to improve the way diseases are diagnosed. and will help patients access the most appropriate treatments more quickly, improve the lives of patients and help the NHS make the best use of its resources. It will also enable a better environment for life sciences and contribute to the UK’s economic growth, consistent with the Government’s Strategy for UK Life Sciences.


Professor Nigel Silman
Senior Business Development Manager, Public Health England and Visiting Professor, University of West England

Dr Divya Chadha Manek
Head of Business Development (Commercial), NIHR Clinical Research Network

Professor Paul Davis
Co-Founder and Chief Scientific Officer, Mologic and Honorary/Visiting Professor, Universities of Cardiff, Kent and Warwick

Dr Matthew Hallsworth
Head of External Relations, NIHR Office for Clinical Research Infrastructure

Dr Karen Kempsell
Senior Project Team Leader, Public Health England

Dr Angela Silmon
Chief Executive Officer, NewGene 

Doris-Ann Williams MBE
Chief Executive, British in vitro Diagnostics Association 


12.15 - 13.00

Top considerations for protecting your innovations through IP continues


Developing and delivering Advanced Therapies – clinical trials are just the start 

This session will explore how to create and maintain value in the development chain for cell and gene therapies. Presenters will discuss how to use patents to secure the value of your product, ways to streamline your supply chain and how to obtain market access and reimbursement.

Dr Sven Kili

Vice President and Head of Cell and Gene Therapy Development, GlaxoSmithKline, and Chair of BIA’s Cell and Gene Therapy Advisory Committee

Simon Ellison
Cell and Gene Therapy, Service Director. World Courier

Dr Panos Kefalas
Head of Health Economics and Market Access, Cell and Gene Therapy Catapult

Dr Jennifer O’Farrell
Partner, Boult Wade

Cooperating to solve the  key diagnostic challenges faced by the NHS continues

13.00 - 14.15

Lunch, networking, exhibition and speed-partnering

14.15 - 15.45

Parallel Tracks

14.15 - 15.00

Maintaining investor and public confidence through good communications

Maintaining investor and public confidence is vital for the continued growth of the UK life sciences sector. Drawing on best practice from across the sector and legal experts, this session will look at how to communicate the results of R&D and regulatory developmentsclearly and accurately across a range of media.

The session is also an opportunity for all BIA members to inform the BIA’s new best practice guide for life science companies communicating market-sensitive information and other R&D developments, which will be published in early 2018.

Dr Chris Gardner
Partner, Consilium Strategic Communications

Sue Charles

Managing Partner, Instinctif Partners Life Sciences

Charles Mayo
Partner, Simmons & Simmons

Nuala Moran
Science Writer

Dr Julie Simmonds
Director, Equity Research, Panmure Gordon

Why the UK is a great place to do translational science

This session will explore the translational research landscape.  Our expert speakers will outline some aspects of the outstanding science-base represented by UK universities and institutions, and the opportunities that these present for translational research and their success in spinning-out companies based on discoveries arising from their academic research.  Following these two 15 minute presentations, both speakers and the chair will then open up the discussion with the audience

Dr Will West
Executive Chairman, CellCentric and BIA Board 

Dr Veronique Birault
Head, Translational Science, The Francis Crick institute 

Prof Jim Huntington
Professor of Molecular Haemostasis, Cambridge University 


Leveraging UK investment and leadership in Genomics

The UK is a global leader in genomics research and a European hub for venture-led technology investment.  Recent technology advances and the establishment of the 100,000 Genomes programme by Genomics England presents a platform to exploit these strengths and support growth of the UK’s genomics industry.  Our panel brings together representatives from the venture community, Genomics England and SMEs to debate the opportunities and challenges that will shape the growth of our genomics industry.

Adrian Ibrahim
Head of Technology Transfer and Business Development, Sanger Institute

Anthony Finbow
Executive Chairman, Eagle Genomics

Professor Joanne Hackett
Commercial Director, Genomics England

Tom Hulme
General Partner, GV

Sumit Jamuar
Chairman and Chief Executive Officer, Global Gene Corp

15.00 – 15.45

International innovation ecosystems: spotlight on key enabling mechanisms in Switzerland and Israel

This session will bring together international perspectives from Israel and Switzerland to discuss different approaches to biotech innovation. Drawing on examples from their own countries, panellists will discuss the key to success for incubator and accelerator programmes, models for fostering effective partnerships between industry and government, how to attract investment and scaling-up beyond the initial stages.

We'll compare the systems in these countries that have led to their worldwide recognition as leading innovators in Life Sciences, and discuss whether the UK can learn anything from these experiences as it navigates the challenges presented by Brexit.

Dr Aleksandra Berditchevskaia
European Coordination and Knowledge Transfer Manager, Tekiu

Yaron Breski 

Managing Director in Life Sciences, RM Global Investment Banking, Israel 

Jonathan Tobin
Investment Manager, Arix Biosciences

Raphaël Tschanz

Deputy Chief Executive Officer, Switzerland Innovation

Moving from good to great - ensuring that the UK remains an important location for early stage clinical trials

A key Regulatory strength in the UK is the openness of the MHRA to novel flexible and adaptive clinical trial design. In this session we will compare and contrast with the Regulatory Authorities in other countries, looking at addressing delays in the UK, and how this can be addressed, as well as what is delaying things in other countries, and how this can be avoided. In addition, a key logistical strength of the UK is the NHS. We will assess what can be further done to showcase this strength globally and consider the opportunities for improvement.

Dr Penny Ward
Chief Medical Officer, Karus Therapeutics 

Dr Matthew Hallsworth
Head of External Relations, NIHR

Dr Ed Hodgkin
Partner, Syncona Partners

Zeshan Ghory
Vice President Operations and Analytics, Antidote

Dr Vijay Reddy
Chief Medical Officer, Autolus 

Kirsty Wydenbach
Deputy Unit Manager and Senior Medical Assessor Clinical Trials Unit, MHRA 

Future innovation in drug discovery at the intersection of biology and technology: strategic and talent challenges for the life sciences

Innovation and new technologies are developing at an unprecedented pace and transforming the art of the possible.  We take a look at the strategic challenges that life science companies (big and small) face when adopting or developing new technologies within drug development, and the organisational challenges of pulling together and incentivising a diverse workforce who may prioritise differently and have different career paths and aspirations.  This panel will draw together companies who are actively tackling these issues and successfully taking innovation forward at the interface of biology and technology.

Hanno Ronte
Partner, Monitor Deloitte

Charlotte Casebourne
Principal, Oxford Sciences Innovation

Dr Tim Fell
Chief Executive Officer, Synthace

Dr James Field
Chief Executive Officer, LabGenius and BBSRC Early Career Impact Winner, Innovator of the Year

Dr Tim Guilliams
Founder and Chief Executive of Healx 

Heather Hayes
Global Head of Human Resources, Horizon Discovery

15.45 - 16.15

Refreshments, networking, exhibition and speed-partnering

16.15 - 17.00

Sources of funding in the post Brexit world

Exiting the UK could leave a big hole in the investing communities resources to invest in the UK's BioIndustry.  At the moment, the European Investment Fund (EIF) makes significant investments in the UK via venture capital firms. Have these sources of funding for investors already started to freeze?  Following the exit of the UK from the EU, what will replace the EIF?  Do the Patient Capital Review and the Life Sciences Industrial Policy go far enough to ensure that the UK's Bio community can continue to access funding? This session will explore these questions and more from the combined perspective or both investors and fundraisers.

Panel discussion with

Steve Bates OBE
Chief Executive Officer, BIA

Jeremy Curnock Cook
Managing Director, BioScience Managers

Laura Ferguson

UK Director, Capital Cell

Alice Hu Wagner
Managing Director, Strategy Economics and Business Development, British Business Bank

Richard Penny
Senior Fund Manager, Legal and General Investment Management

Paul Tomasic
Managing Director, European Head of Healthcare, RBC Capital Markets

17.00 - 17.45

Brexit progress report and looking to 2018

Since the outcome of the referendum BIA has been working in conjunction with the ABPI to ensure that the priorities of our sector are understood by Government and represented in their work.  This panel will look back on the progress that we have made, in particular in the areas of regulation and trade.

We are also planning our work for the coming year and we would welcome members’ input to help us develop this work.  In the next 12 months, we anticipate focusing on the movement of people and a possible new immigration system and the future of research collaboration and finance for our sector.

Steve Bates OBE
Chief Executive Officer, BIA

Dr Virginia Acha

Executive Director Research, Medical and Innovation, ABPI

David Boyd
Director European Government Affairs, AstraZeneca

Laura Collister
Brexit Lead, BIA

Alan Morrison
Vice President Regulatory Affairs International, Merck Sharp & Dohme (MSD)

17.45 - 17.50

Summary and Close

18.00 - 18.30

BIA AGM (BIA members Only)

18.00 - 21.00

BIA Autumn Reception - Connecting the bioscience community